A novel tyrosine kinase inhibitor (TKI), asciminib, is showing promising clinical activity in patients with CML who have primary intolerance to prior TKI therapy, Australian research shows. Professor Timothy Hughes, Precision Medicine Theme Leader at the South Australian Health and Medical Research Institute (SAHMRI) presented new results at EHA25 Virtual from a phase 1 study ...
Novel TKI effective in CML patients intolerant to previous therapies
By Michael Woodhead
23 Jun 2020